What is 3Daughters?
3Daughters operates as a specialized clinical development firm dedicated to advancing women's health through rigorous research and technological breakthroughs. The company is currently focused on solving critical, often overlooked health issues, with a primary objective of eliminating the primary barrier to IUD adoption: insertion pain. By applying a patient-centric design philosophy to medical device development, 3Daughters aims to transform the standard of care for millions of women globally.
The company's market position is defined by its commitment to high-impact innovation in a sector that has historically suffered from underinvestment. By bridging the gap between academic research and commercial application, 3Daughters is effectively disrupting the traditional medical device landscape, ensuring that women's health receives the attention and resources necessary for meaningful progress.
How much funding has 3Daughters raised?
3Daughters has raised a total of $6.7M across 1 funding round:
Angel/Seed
$6.7M
Angel/Seed (2024): $6.7M with participation from Argosy Foundation, University of Massachusetts - Amherst, Thairm Bio, and Wexford Science & Technology
Key Investors in 3Daughters
Argosy Foundation
A private family foundation that supports creative and entrepreneurial solutions to systemic challenges across health, education, and the arts.
University of Massachusetts - Amherst
A public research and land-grant university that fosters academic innovation and supports the commercialization of breakthrough research.
Wexford Science & Technology
A developer of mixed-use knowledge communities that collaborates with research institutions to accelerate discovery and technological advancement.
What's next for 3Daughters?
With the recent capital injection, 3Daughters is poised to transition from early-stage research into more advanced clinical development phases. The strategic roadmap involves scaling its R&D capabilities and navigating the regulatory pathways required to bring its pain-reducing IUD technology to market. This major enterprise-level funding provides the necessary runway to conduct comprehensive clinical trials and refine its proprietary technology.
Looking ahead, the company is expected to leverage its partnerships with research institutions and innovation-focused investors to solidify its intellectual property portfolio. As 3Daughters continues to scale, the focus will remain on achieving clinical validation and establishing a robust commercialization strategy that addresses the systemic gaps in women's reproductive health, ultimately setting a new benchmark for medical device efficacy and patient comfort.
